Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.

Maria Yu¹, Reema Mody², Laura Fernández Landó³, Amy Shui⁴, Lee Kallenbach⁴, Lukas Slipski⁴, Carolina Piras de Oliveira³

¹Eli Lilly and Company, Toronto, Ontario, Canada. Electronic address: yu_maria@lilly.com.

²Eli Lilly and Company, Corporate Center, Indianapolis, Indiana.

³Lilly USA, LLC, Corporate Center, Indianapolis, Indiana.

⁴Practice Fusion, San Francisco, California.

PubMed DOI

Abstract

PURPOSE: The objective of this retrospective observational study was to describe and identify clinical and demographic characteristics associated with the choice of first injectable therapy (glucagon-like peptide-1 receptor agonist [GLP-1-RA] or basal insulin) among patients with type 2 diabetes mellitus (T2DM). METHODS: This analysis included adults naive to injectable therapy with T2DM who init…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.